The effect of indomethacin on the kinetics of histamine, 48/80 and antigen wealing.
1. The kinetics of weal formation and disappearance following intradermal injection of histamine, compound 48/80 and antigen were measured in indomethacin and inert geltreated human forearm skin. 2. Rates of formation went in descending order for histamine, 48/80 and antigen; rate constants of disappearance for equal sized weals were the same for histamine and 48/80 but were much less for antigen. The corresponding half-lives were 77, 73 and 160 min for histamine, 48/80 and antigen weal disappearance respectively. 3. Cyclo-oxygenase inhibition by topical indomethacin had no effect either on the immediate weal and flare responses or on the rates of formation and disappearance of the weals. 4. These findings together with previous studies using H1-receptor antagonists indicate that 48/80 acts by histamine release but that antigen releases both histamine and an additional material or materials which are not related to cyclo-oxygenase activity. 5. Exacerbation of chronic idiopathic urticaria by cyclo-oxygenase inhibitors is therefore likely to be part of the urticarial disease process.
Humphreys
F
F
University Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne.
Shuster
S
S
D000328:Adult; D000818:Animals; D016861:Cyclooxygenase Inhibitors; D003872:Dermatitis / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006632:Histamine / Q000493:pharmacokinetics*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D007271:Injections, Intradermal; D008297:Male; D008925:Mites / Q000276:immunology; D014581:Urticaria / Q000503:physiopathology; D003189:p-Methoxy-N-methylphenethylamine / Q000493:pharmacokinetics*
D016861:Cyclooxygenase Inhibitors; D003189:p-Methoxy-N-methylphenethylamine; D006632:Histamine; D007213:Indomethacin